文献速递核素与放射性配体治疗肿瘤 PET/CT

小鼠模型与注射配体摩尔量对PSMA放射性配体组织分布的影响

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-08-17

该临床前研究比较了[177Lu]Lu-Ibu-DAB-PSMA和[177Lu]Lu-PSMA-617在不同实验条件下的表现,发现低摩尔浓度配体增加两种肿瘤细胞摄取且高浓度饱和效应在PSMA低表达的LNCaP细胞更明显,体内PC-3 PIP肿瘤摄取均高于LNCaP肿瘤,低配体量主要增加[177Lu]Lu-Ibu-DAB-PSMA的PC-3 PIP肿瘤摄取但对LNCaP肿瘤两种配体均受配体量影响,且低配体量给药后最初几小时肾脏滞留高达四倍。结论强调肿瘤模型和配体用量对PSMA放射性配体表征的重要性,统一临床前设计对比较新配体与现有配体及预测临床优势至关重要。

要点

  • 低摩尔浓度配体增加PC-3 PIP和LNCaP细胞摄取,高浓度饱和效应在LNCaP更明显。
  • 所有时间点PC-3 PIP肿瘤的体内摄取均高于LNCaP肿瘤。
  • 低配体量主要增加[177Lu]Lu-Ibu-DAB-PSMA的PC-3 PIP肿瘤摄取,LNCaP肿瘤两种配体均受配体量影响。

核心结论

  • 肿瘤模型和注射配体量对PSMA放射性配体的临床前表征有重要影响。
  • 采用统一的临床前研究设计对于比较新型放射性配体与现有配体并预测临床优势至关重要。

研究设计与样本

  • 体外细胞摄取研究使用PC-3 PIP和LNCaP肿瘤细胞,配体摩尔浓度范围0.75-500 nM。
  • 体内生物分布和SPECT/CT成像研究使用相应肿瘤小鼠模型,每只小鼠注射0.05 nmol和1.0 nmol配体。

主要发现

  • 两种肿瘤细胞系中,使用低摩尔浓度配体时摄取增加。
  • 高配体浓度下的饱和效应在PSMA低表达的LNCaP细胞中比PC-3 PIP细胞更明显。
  • 所有研究时间点,两种放射性配体在PC-3 PIP肿瘤中的体内摄取均高于LNCaP肿瘤。
  • 低摩尔量注射配体主要增加[177Lu]Lu-Ibu-DAB-PSMA的PC-3 PIP肿瘤摄取;使用LNCaP肿瘤时配体摩尔量对两种配体均相关。
  • 与高配体量相比,低配体量给药后最初几小时两种配体的肾脏滞留高达四倍。

临床怎么用

  • 临床前评估PSMA放射性配体时应考虑肿瘤模型和注射配体量的影响。
  • 比较新型与现有PSMA放射性配体时应采用统一的研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Various preclinical study designs are described in the literature for the evaluation of PSMA radioligands. In this study, [177Lu]Lu-Ibu-DAB-PSMA, an albumin-binding radioligand, and [177Lu]Lu-PSMA-617 were investigated and compared under variable experimental conditions. METHODS: In vitro cell uptake studies were performed with PC-3 PIP and LNCaP tumor cells using a range of molar concentrations (0.75-500 nM) of both radioligands. Biodistribution and SPECT/CT imaging studies were carried out with the respective tumor mouse models using 0.05 nmol and 1.0 nmol injected ligand per mouse. RESULTS: In both tumor cell lines, the uptake of the radioligands was increased when using low molar concentrations of the respective ligand. The observed saturation effect at high ligand concentrations was more pronounced for LNCaP cells that express PSMA at lower levels than for PC-3 PIP cells. At all investigated timepoints, the in vivo uptake of both radioligands was higher in PC-3 PIP tumors than in LNCaP tumors. A low molar amount of injected ligand increased the PC-3 PIP tumor uptake mainly for [177Lu]Lu-Ibu-DAB-PSMA; however, the molar amount of ligand was relevant for both radioligands when using LNCaP tumors. Renal retention of both radioligands was, however, up to fourfold higher during the first hours after application of a low ligand amount compared to the high ligand amount. CONCLUSION: The results of this preclinical study underline the relevance of the tumor model and applied ligand amount for the characterization of PSMA radioligands. The application of equal preclinical study designs is crucial to allow the comparison of novel radioligands with existing ones and, thus, predict potential advantages of new radioligands in view of a clinical application.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tschan VJ, Borgna F, Schibli R, et al. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. Eur J Nucl Med Mol Imaging. 2021. PMID: 34402925. doi:10.1007/s00259-021-05446-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。